Celltrion Pharm partially recalls Ganejin
Predicted impact: Low
Japanese version of the same partial Ganejin recall already reported in Korean.
Celltrion Pharm셀트리온제약
068760 · KOSDAQ · ₩068760 · 셀트리온제약
₩37,100▲ ₩550 (1.50%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −42.92%
- Market cap
- ₩1.6T
- Enterprise value
- ₩1.7T
- P/E
- 39.8×
- P/B
- 3.7×
- Dividend yield
- 0.5%
- ROE
- 9.2%
- Net margin
- 7.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−52.6% from the high
₩35,600Today: ₩36,700 – ₩37,600₩78,300
Returns
- 1W−5.7%
- 1M−5.7%
- 3M−3.6%
- 6M−35.7%
- YTD−36.0%
- 1Y−42.9%
- Volume today
- 34,231
- 0.5× the 20-day average
- Traded today
- ₩1.3B
- Listed shares
- 44,402,332
- EPS (12 months)
- ₩932
- Earnings yield 2.5%
AI research · InitiationCelltrion Pharm: Steady Profit Growth, Shares Down 28.8% Over a Year, Model Estimate Below PriceThe filings show a company with growing revenue, recovering margins and positive free cash flow, set against a sharp one-year share price decline and a model estimate below the current price.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 32 of 100 (50 is a normal day for this stock).
- MomentumFlat-5% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩2.7B at the close (97.4% of 20-day average trading value)
On its 13 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 63.0% of trading value and pointed the same way 10 of 13 times.
- 2× KODEX KOSDAQ150 Leverage ₩2.4B
- -1× KODEX KOSDAQ150 Futures Inverse ₩137M
- 2× TIGER KOSDAQ150 Leverage ₩125M
- 2× RISE KOSDAQ150 Futures Leverage ₩24M
- -1× TIGER KOSDAQ150 Futures Inverse ₩4.5M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.6%
- KODEX KOSDAQ150 Leverage2×0.6%
- TIGER KOSDAQ1500.6%
- RISE KOSDAQ1500.6%
- TIGER KOSDAQ150 Leverage2×0.6%
- ACE KOSDAQ 1500.6%
- KIWOOM KOSDAQ1500.6%
- SOL KOSDAQ1500.6%
Estimated from the funds' index or underlying stock.
Futures and options
All stock futures →Futures (2026-11): 37,050
Basis −0.13% · implied rate −3.3%
Open interest 1,028 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
Celltrion Pharm stock overview
Celltrion Pharm (셀트리온제약, KRX: 068760) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures prescription pharmaceuticals, including tablets and hard capsules, at facilities in Jincheon and Osong in Chungcheongbuk-do, South Korea, and holds GMP certifications from Korea, the United States and the European Union. Its shares closed at ₩37,100 on Oct 28, 2026, up 1.50% on the day, giving it a market value of ₩1.6T.
Key facts
- Market cap
- ₩1.6T
- Sector
- Biotech & Pharma
- Latest price change
- +1.50%
- As of
- Oct 28, 2026
- Main business
- The company manufactures prescription pharmaceuticals, including tablets and hard capsules, at facilities in Jincheon and Osong in Chungcheongbuk-do, South Korea, and holds GMP certifications from Korea, the United States and the European Union.
Quick answers about Celltrion Pharm
- What does Celltrion Pharm do?
- The company manufactures prescription pharmaceuticals, including tablets and hard capsules, at facilities in Jincheon and Osong in Chungcheongbuk-do, South Korea, and holds GMP certifications from Korea, the United States and the European Union. It also operates a prefilled syringe production line for biopharmaceuticals at its Osong site and offers process development services. The company sells chemical drugs such as the liver treatment Gedex and holds exclusive domestic sales rights for 12 biopharmaceutical products developed by its parent company Celltrion, including autoimmune and cancer treatments, and also exports some products.
- What is the market cap of Celltrion Pharm?
- The market capitalisation of Celltrion Pharm was ₩1.6T at the close on Oct 28, 2026.
- Who are the largest shareholders of Celltrion Pharm?
- According to the latest official filings, the largest reported holders are Celltrion (55.50%, as of Apr 10, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.73%, as of Jul 31, 2026); iShares Core MSCI Emerging Markets ETF (0.51%, as of May 31, 2026).
- When is the next earnings report from Celltrion Pharm?
- Korean companies rarely announce results dates in advance. Based on when Celltrion Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Celltrion Pharm?
- Yes. The National Pension Service held 0.49% of Celltrion Pharm shares as of Dec 31, 2025.
Company profile
The company manufactures prescription pharmaceuticals, including tablets and hard capsules, at facilities in Jincheon and Osong in Chungcheongbuk-do, South Korea, and holds GMP certifications from Korea, the United States and the European Union. It also operates a prefilled syringe production line for biopharmaceuticals at its Osong site and offers process development services. The company sells chemical drugs such as the liver treatment Gedex and holds exclusive domestic sales rights for 12 biopharmaceutical products developed by its parent company Celltrion, including autoimmune and cancer treatments, and also exports some products.
Written by AI from the company's latest annual report.
- Korean name
- 셀트리온제약
- Sector
- Biotech & Pharma
- Themes
- Biosimilars
- Business group
- Celltrion
- CEO
- 유영호
- Founded
- Nov 2000
- Listed
- Feb 2006
- Listed shares
- 44,402,332
- Fiscal year ends
- Month 12
- Website
- www.celltrionph.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
[Exclusive] "Supposed to be really good for the liver"… Celltrion Pharm voluntarily recalls some Ganejin products
Predicted impact: Medium
Voluntary recall of some health products; partial scope and limited revenue impact indicated.
Recent filings
See all- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 27, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 14, 2026
- Preliminary earningsAug 4, 2026
- Future Business and Management Plans (Fair Disclosure)Jul 2, 2026
Titles in Korean until English translations are added.
Also known as: Celltrion Pharm / 셀트리온제약 / 068760 / KRX:068760
Source: KRX statistical information